Advertisement

ADVERTISEMENT

Noncolorectal

News
Comprehensive Molecular Panel Testing in GI Cancers
09/26/2020
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
At the Great Debates & Updates...
09/26/2020
Oncology
Current and Emerging Therapy Options in Pancreatic Cancer
Videos
Current and Emerging Therapy Options in Pancreatic Cancer
09/26/2020
Jordan Berlin, MD, shares an overview of new treatment options and trials in pancreatic cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Jordan Berlin, MD, shares an overview of new treatment options and trials in pancreatic cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Jordan Berlin, MD, shares an...
09/26/2020
Oncology
Yelena Janjigian, MD, Discusses HER2-Targeting Updates for Metastatic/Locally Advanced Esophageal, Gastric Cancers
Videos
Yelena Janjigian, MD, Discusses HER2-Targeting Updates for Metastatic/Locally Advanced Esophageal, Gastric Cancers
07/28/2020
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Dr Janjigian shares her...
07/28/2020
Oncology
Conference Insider
Ripretinib Yields Clinically Meaningful Benefit in Advanced GIST
07/07/2020
Patients given ripretinib for advanced GIST in the INVICTUS trial had improved PFS and OS, according to data presented at the virtual ESMO World Congress on GI Cancer.
Patients given ripretinib for advanced GIST in the INVICTUS trial had improved PFS and OS, according to data presented at the virtual ESMO World Congress on GI Cancer.
Patients given ripretinib for...
07/07/2020
Oncology
Deborah Mukherji, MD, Talks Gaps in Research and Potential for Further Study on HCC, Biliary Tract Cancers
Videos
Deborah Mukherji, MD, Talks Gaps in Research and Potential for Further Study on HCC, Biliary Tract Cancers
07/04/2020
Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Dr Mukherji summarizes 3 posters...
07/04/2020
Oncology
First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC
Podcasts
First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC
07/02/2020
Zev Wainberg, MD, discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for PDAC.
Zev Wainberg, MD, discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for PDAC.
Zev Wainberg, MD, discusses...
07/02/2020
Oncology
Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
Videos
Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
07/01/2020
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Dr Ramaswamy provides...
07/01/2020
Oncology
Conference Insider
Similar Outcomes With Maintenance Olaparib for gBRCA-Mutated Pancreatic Cancer, Regardless of Patient Age
07/01/2020
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
The safety of maintenance...
07/01/2020
Oncology
News
Infigratinib Yields PFS, ORR Benefit in Patients With Cholangiocarcinoma and FGFR2 Fusions
07/01/2020
In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.
In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.
In a phase 2 trial, third- and...
07/01/2020
Oncology
Conference Insider
Experts Develop Nomogram That Predicts Survival in Patients With Unresectable Pancreatic Cancer
07/01/2020
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Findings from a study presented...
07/01/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use